Escitalopram for the Treatment of Self-Injurious Skin Picking

NCT00115011 | Completed Phase 4

• 3 other identifiers: 2002-P-000888LXP-MD-361200-211220
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.

Conditions

Impulse Control Disorders

Keywords

Skin Picking; Escitalopram; Lexapro; Body Focused Repetitive Behaviors; Obsessive Compulsive Spectrum Disorders

Outcome Measures

Primary Outcomes (4)

• MGH Skin Picking Scale

• Skin Picking Impact Scale

• Skin Picking Treatment Scale

• Clinical Global Impressions scale

Secondary Outcomes (4)

• Hamilton Depression Rating

• Beck Depression Inventory

• Beck Anxiety Inventory

• Quality of Life Enjoyment and Satisfaction Scale

Interventions

Escitalopram DRUG

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Repetitive skin picking resulting in noticeable tissue damage and associated emotional distress and/or functional impairment.
• Age 18-65 years old.
• Duration of skin picking symptoms ≥ 6 months.
• MGH Skin Picking Scale score ≥ 10.
• Written informed consent.
• Females of childbearing potential must have a negative serum or urinary beta-HCG test and be willing to use acceptable methods of birth control during study tenure.

You may not qualify if:

• Pregnant women or females of childbearing potential who do not consent to use of a medically acceptable method of contraception.
• Women who are breastfeeding.
• Subjects who pose a serious suicidal or homicidal risk in the judgment of study investigators.
• Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease.
• Subjects with a dermatologic disorder that causes pruritis.
• Patients on anticoagulant therapy.
• History of seizure disorder.
• Comorbid bipolar disorder, psychosis, organic mental disorder, borderline personality disorder or developmental disorder. Subjects with obsessive compulsive disorder (with primary symptoms other than compulsive skin picking).
• History of substance dependence. If there is a history of substance abuse, subjects should be in remission for ≥ 6 months.
• Current treatment with cognitive behavioral therapy for skin picking.
• Current use of another SSRI medication.
• Other medications for medical disorders that might interfere with escitalopram.
• Current major depression or prescribed an antidepressant for major depression within the past 12 months.
• More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another prior SSRI.

Sponsors & Collaborators

• Massachusetts General Hospital: lead
• Forest Laboratories: collaborator

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Related Publications (6)

• Gupta MA, Gupta AK, Haberman HF. Neurotic excoriations: a review and some new perspectives. Compr Psychiatry. 1986 Jul-Aug;27(4):381-6. doi: 10.1016/0010-440x(86)90014-3. No abstract available.

  PMID: 3731771 BACKGROUND

• Keuthen NJ, Deckersbach T, Wilhelm S, Hale E, Fraim C, Baer L, O'Sullivan RL, Jenike MA. Repetitive skin-picking in a student population and comparison with a sample of self-injurious skin-pickers. Psychosomatics. 2000 May-Jun;41(3):210-5. doi: 10.1176/appi.psy.41.3.210.

  PMID: 10849452 BACKGROUND

• O'Sullivan RL, Phillips KA, Keuthen NJ, Wilhelm S. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics. 1999 Jan-Feb;40(1):79-81. doi: 10.1016/S0033-3182(99)71276-4. No abstract available.

  PMID: 9989126 BACKGROUND

• Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry. 1997 Aug;58(8):341-7. doi: 10.4088/jcp.v58n0802.

  PMID: 9515971 BACKGROUND

• Kalivas J, Kalivas L, Gilman D, Hayden CT. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol. 1996 May;132(5):589-90. doi: 10.1001/archderm.1996.03890290131022. No abstract available.

  PMID: 8624163 BACKGROUND

• Arnold LM, Mutasim DF, Dwight MM, Lamerson CL, Morris EM, McElroy SL. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol. 1999 Feb;19(1):15-8. doi: 10.1097/00004714-199902000-00005.

  PMID: 9934938 BACKGROUND

MeSH Terms

Conditions

Disruptive, Impulse Control, and Conduct Disorders; Excoriation Disorder

Interventions

Escitalopram

Condition Hierarchy (Ancestors)

Mental Disorders; Self-Injurious Behavior; Behavioral Symptoms; Behavior; Obsessive-Compulsive Disorder; Anxiety Disorders

Intervention Hierarchy (Ancestors)

Propylamines; Amines; Organic Chemicals; Nitriles; Benzofurans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Nancy J Keuthen, Ph.D.

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: June 20, 2005
• First Posted: June 21, 2005
• Study Start: September 1, 2002
• Study Completion: November 1, 2005
• Last Updated: May 20, 2008

Record last verified: 2008-05

Locations

US (1)